{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:42:11Z","timestamp":1793472131157,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.seizure.2020.07.014","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:13:04Z","timestamp":1597410784000},"page":"133-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5142-8769","authenticated-orcid":false,"given":"Janthima","family":"Methaneethorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-4775","authenticated-orcid":false,"given":"Nattawut","family":"Leelakanok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.seizure.2020.07.014_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.seizure.2020.07.014_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FTD.0000000000000279","article-title":"Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma lamotrigine concentration at week 2","volume":"38","author":"Nakamura","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"Lamotrigine","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00023210-200418010-00007","article-title":"Spotlight on lamotrigine in bipolar disorder","volume":"18","author":"Goldsmith","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(96)00265-8","article-title":"Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications","volume":"307","author":"Stefani","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"10.1016\/j.seizure.2020.07.014_bib0030","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1097\/00001756-199611250-00048","article-title":"Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones","volume":"7","author":"Wang","year":"1996","journal-title":"Neuroreport"},{"issue":"11","key":"10.1016\/j.seizure.2020.07.014_bib0035","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0028-3908(00)00051-4","article-title":"The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro","volume":"39","author":"Cunningham","year":"2000","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.seizure.2020.07.014_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000026527","article-title":"Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder","volume":"38","author":"Xie","year":"1998","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy","volume":"39","author":"Grasela","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0055","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1528-1157.1999.tb01990.x","article-title":"Lamotrigine concentrations in human serum, brain tissue, and tumor tissue","volume":"40","author":"Meyer","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.07.014_bib0060","series-title":"Clinical Pharmacokinetics","author":"Murphy","year":"2011"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00003495-199346010-00009","article-title":"Lamotrigine","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","article-title":"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans","volume":"42","author":"Cohen","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2020.07.014_bib0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(91)90012-5","article-title":"Pharmacokinetics and safety of lamotrigine (Lamictal\u00ae) in patients with epilepsy","volume":"10","author":"Ramsay","year":"1991","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2020.07.014_bib0080","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2020.07.014_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","article-title":"UGT2B7_\u2212 161C& T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study","volume":"32","author":"S\u00e1nchez","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.seizure.2020.07.014_bib0095","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service","volume":"46","author":"Morris","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children","volume":"50","author":"Chen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/acn3.29","article-title":"Model-based lamotrigine clearance changes during pregnancy: clinical implication","volume":"1","author":"Polepally","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2020.07.014_bib0120","doi-asserted-by":"crossref","DOI":"10.1111\/j.1535-7511.2005.05303.x","article-title":"Making sense of lamotrigine serum levels","volume":"5","author":"Abou-Khalil","year":"2005","journal-title":"Epilepsy Curr"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40268-016-0148-6","article-title":"An updated overview on therapeutic drug monitoring of recent antiepileptic drugs","volume":"16","author":"Jacob","year":"2016","journal-title":"Drugs in R&D"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199310000-00005","article-title":"Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control","volume":"15","author":"Jelliffe","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-013-1606-5","article-title":"Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients - Nonlinear mixed effects modelling approach","volume":"70","author":"Brzakovi\u0107","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0140","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","article-title":"A population pharmacokinetic-pharmacogenetic model of lamotrigine in Chinese children with epilepsy","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","article-title":"Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy","volume":"42","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.1016\/j.seizure.2020.07.014_bib0155","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","article-title":"Population pharmacokinetics of lamotrigine in Chinese children with epilepsy","volume":"33","author":"He","year":"2012","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","article-title":"Population pharmacokinetics of lamotrigine in Indian epileptic patients","volume":"69","author":"Mallaysamy","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.seizure.2020.07.014_bib0165","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5414\/CPP47752","article-title":"Population pharmacokinetics of lamotrigine in patients with epilepsy","volume":"47","author":"Molivanovic","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","article-title":"Population pharmacokinetics of lamotrigine in elderly patients","volume":"48","author":"Punyawudho","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in german and spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0180","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","article-title":"Influence of the UGT2B7-161C&T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients","volume":"69","author":"Singkham","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0185","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-018-2414-8","article-title":"Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-016-2190-2","article-title":"Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy","volume":"73","author":"Zhang","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2020.07.014_bib0195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated?","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.seizure.2020.07.014_bib0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","article-title":"Overview of model\u2010building strategies in population PK\/PD analyses: 2002\u20132004 literature survey","volume":"64","author":"Dartois","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2020.07.014_bib0210","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14272","article-title":"A systematic review of population pharmacokinetic analyses of digoxin in the pediatric population","author":"Abdel\u2010Jalil","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2020.07.014_bib0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","author":"Milosheska","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000066165","article-title":"Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures","volume":"48","author":"Benetello","year":"2002","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0225","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1345\/aph.1A252","article-title":"Therapeutic drug monitoring of lamotrigine","volume":"36","author":"Chong","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0230","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2020.07.014_bib0235","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"1_suppl","key":"10.1016\/j.seizure.2020.07.014_bib0240","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine: pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"Journal of child neurology"},{"issue":"12","key":"10.1016\/j.seizure.2020.07.014_bib0245","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.118.083030","article-title":"Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function, and drug pharmacokinetics","volume":"46","author":"Heyes","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"01\/02","key":"10.1016\/j.seizure.2020.07.014_bib0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.seizure.2020.07.014_bib0260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.seizure.2008.05.009","article-title":"Smoking reduces serum levels of lamotrigine","volume":"17","author":"Reinsberger","year":"2008","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0265","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5497\/wjp.v8.i2.14","article-title":"Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine","volume":"8","author":"Maideen","year":"2019","journal-title":"World J Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2020.07.014_bib0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2133\/dmpk.DMPK-13-RG-105","article-title":"Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism","volume":"29","author":"Ohkura","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1016\/j.seizure.2020.07.014_bib0275","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"46","key":"10.1016\/j.seizure.2020.07.014_bib0280","doi-asserted-by":"crossref","first-page":"36164","DOI":"10.1074\/jbc.M002180200","article-title":"Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine","volume":"275","author":"Strassburg","year":"2000","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.seizure.2020.07.014_bib0285","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0016-5085(99)70239-8","article-title":"UDP-glucuronosyltransferase activity in human liver and colon","volume":"116","author":"Strassburg","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0290","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/mol.52.2.212","article-title":"Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification ofUGT1A7 and UGT1A10 transcripts in extrahepatic tissue","volume":"52","author":"Strassburg","year":"1997","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2020.07.014_bib0295","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/bj3380489","article-title":"Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus","volume":"338","author":"STRASSBURG","year":"1999","journal-title":"Biochem J"},{"issue":"15","key":"10.1016\/j.seizure.2020.07.014_bib0300","doi-asserted-by":"crossref","first-page":"8719","DOI":"10.1074\/jbc.273.15.8719","article-title":"Expression of the UDP-glucuronosyltransferase 1A locus in human colon identification and characterization of the novel extrahepatic UGT1A8","volume":"273","author":"Strassburg","year":"1998","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.seizure.2020.07.014_bib0305","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0026-895X(24)13065-9","article-title":"Polymorphic expression of the UDP-GlucuronosyltransferaseUGT1A gene locus in human gastric epithelium","volume":"54","author":"Strassburg","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.seizure.2020.07.014_bib0310","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3389\/fphar.2019.00832","article-title":"Effects of comedication and genetic factors on the population pharmacokinetics of lamotrigine: a prospective analysis in chinese patients with epilepsy","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120302168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120302168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:57:20Z","timestamp":1761011840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120302168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":62,"alternative-id":["S1059131120302168"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.07.014","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}